In July 2012 The follow-up period ended. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsDiagnosing traumatic brain injury through a blood check: an interview with Dr KorleyLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. Klegerman All patients received 150 mg of aliskiren or placebo daily, furthermore to standard therapy. The study drug was continued after discharge for a median 11.3 months. The final group for efficacy analyses included 1,615 patients .Of the 68 operators who participated in the trial, 34 performed PCI at hospitals with on-site cardiac operation only, and 34 performed procedures at both types of hospitals. Patients Between 7 July, 2006, and September 29, 2011, a total of 3691 eligible patients were randomly assigned to undergo PCI at a medical center without on-site cardiac surgical treatment or at a medical center with on-site cardiac surgical procedure . A total of 37 patients who underwent randomization didn’t undergo PCI , and 24 patients crossed over and underwent PCI at a site other than the one to which they had been assigned ; the nice reasons are listed in the Supplementary Appendix.